

## Additional file 1

### IN VITRO EFFECTS OF INTERLEUKIN (IL)-1 BETA INHIBITION ON THE EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) OF RENAL TUBULAR AND HEPATIC STELLATE CELLS.

Valentina Masola<sup>\*1</sup>, Amedeo Carraro<sup>\*2</sup>, Simona Granata<sup>1</sup>, Lorenzo Signorini<sup>1</sup>, Gloria Bellin<sup>1</sup>, Paola Violi<sup>2</sup>, Antonio Lupo<sup>1</sup>, Umberto Tedeschi<sup>2</sup>, Maurizio Onisto<sup>3</sup>, Giovanni Gambaro<sup>4</sup>, Gianluigi Zaza<sup>1</sup>.

<sup>1</sup> Renal Unit, Department of Medicine, University-Hospital of Verona, Piazzale Stefani 1, 37126, Verona, Italy;

<sup>2</sup> Department of General Surgery and Odontoiatrics, Liver Transplant Unit, University Hospital of Verona, Piazzale Stefani 1, 37126, Verona, Italy;

<sup>3</sup> University of Padova, Department of Biomedical Sciences, Via Ugo Bassi, 58/B, 35131, Padova, Italy;

<sup>4</sup> Division of Nephrology and Dialysis, Columbus-Gemelli Hospital Catholic University, School of Medicine, Largo Agostino Gemelli 8, 00168, Rome, RM, Italy.

\*These authors contributed equally to this work.


## Additional Method

### Gene expression analysis for Mmp-9


Both cell types were treated with TGF- $\beta$  (10 ng/ml) or IL-1 $\beta$  (10 ng/ml) in the presence or absence of Canakinumab (5  $\mu$ g/ml) for 6 hours. Then, whole RNA was extracted using Trizol reagent (Invitrogen), following the manufacturer's instructions. Quantity and quality of RNA were checked using the Nanodrop spectrophotometer (EuroClone). Total RNA was reverse-transcribed into cDNA using the reverse transcriptase SuperScript II (Invitrogen). Real Time-PCR reactions were performed with the ABI-Prism 7500 using Power SYBR Green Master Mix 2 (Applied Biosystem) and specific primers for *Mmp-9* and *Glyceraldehyde-3-phosphate dehydrogenase* (*Gapdh*). The primer sequences for *Mmp-9* was: Forward 5'- CCTGGAGACCTGAGAACCAATC-3' and reverse 5'- CCACCCGAGTGTAACCATAGC-3'. The comparative Ct method ( $\Delta\Delta$ Ct) was used to quantify gene expression, and the relative quantification was calculated as  $2^{-\Delta\Delta$ Ct}. The GAPDH gene amplification was used as a

reference standard to normalize the target signal. Amplification specificity was controlled by melting curve analysis.


## Additional results




**Figure S1. Gene expression of Metalloproteinase-9 (Mmp-9) in HK-2.** Gene expression of *Mmp-9* measured by Real Time-PCR in HK-2 cells treated with IL-1β or TGF-β with and without Canakinumab. Expression levels are normalized to *Gapdh*. Data are indicated as mean±SD of three experiments performed in triplicate. The p value was calculated with the t-test. \*\*p<0.001 versus untreated control cells (CTR); °°p<0.01 vs TGF-β untreated.



**Figure S2. Enzymatic activity of MMP-9 in HK-2. (A)** Gelatin zymography shows the activity of MMP-9 in the conditioned media of HK-2 cells treated for 24 h with TGF- $\beta$  (10 ng/ml) or IL-1 $\beta$  (10 ng/ml) in the presence or absence of Canakinumab (5  $\mu$ g/ml). **(B)** The histogram represents the densitometric analysis of enzymatic activity of MMP-9 as a mean $\pm$ SD of three experiments. The p value was calculated with the t-test. \*\*p<0.001 versus untreated control cells (CTR); °°p<0.01 vs TGF- $\beta$  untreated; ##p<0.01 vs IL-1 $\beta$  untreated.



**Figure S3. Gene expression of Metalloproteinase-9 (MMP-9) in LX-2.** Gene expression of *Mmp-9* measured by Real Time-PCR in LX-2 cells treated with IL-1β or TGF-β with and without Canakinumab. Expression levels are normalized to *Gapdh*. Data are indicated as mean±SD of three experiments performed in triplicate. The p value was calculated with the t-test. \*\*p<0.001 versus untreated control cells (CTR); °p<0.05 vs TGF-β untreated; #p<0.05 vs IL-1β untreated.



**Figure S4. Enzymatic activity of MMP-9 in LX-2.** Gelatin zymography shows the activity of MMP-9 in the conditioned media of LX-2 cells treated for 24 h with TGF-β (10 ng/ml) or IL-1β (10 ng/ml) in the presence or absence of Canakinumab (5 μg/ml). MMP-9 activity was not detectable in this cell line.